Efficacy and safety of nab-paclitaxel plus carboplatin in patients with Carcinoma of unknown primary site
Phase 2
Recruiting
- Conditions
- Carinoma of unknown primary site(CUP)
- Registration Number
- JPRN-UMIN000016728
- Lead Sponsor
- Teikyo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Indication for radical operation and radiotherapy. 2)Patients unable to take nab-paclitaxel and CBDCA because of significant cardiovascular abnormalities, renal dysfunctions, hepatic insufficiency, uncontrolled diabetes, uncontrolled hypertension, bleeding tendency, active interstitial pneumonia,etc. 3)Known active brain metastasis. 4)Acute or subacute idiopathic interstitial pneumonia 5)Patient received a bone-marrow transplantation 6)Patient received a peripheral stem cell transplantation 7)Known hypersensitivity to any drugs 8)Seropositivity for HBsAg 9)Pregnancy or breast feeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year survival rate
- Secondary Outcome Measures
Name Time Method progression free survival, overall survival,response rate,tumor control rate,adverse event,QO